Business Context and Reporting Period
This Form 6-K filing by Takeda Pharmaceutical Company Limited, dated August 8, 2019, serves as an update to the consolidated financial statements (IFRS) for the three-month period ended June 30, 2019. The filing corrects specific misstatements in the report originally filed on July 31, 2019, with the Tokyo Stock Exchange.
Key Financial Metrics
The filing does not provide new revenue, profit, cash flow, or debt figures. It specifically addresses corrections to the presentation of financial data rather than reporting new operational results.
- Financial Income/Expenses: A correction of 4.5 billion yen related to purchase accounting for the Shire acquisition was identified.
- Cash and Cash Equivalents: A transposition error was corrected in the English translation of the Condensed Interim Consolidated Statement of Cash Flows regarding the ending balance.
Material Changes Versus Prior Period
The filing explicitly states that the corrections do not materially impact the financial statements.
- Operating Income: The misstatement regarding the 4.5 billion yen in Shire acquisition-related costs did not impact Reported or Core Operating Income amounts.
- Cash Flow: The error in the Statement of Cash Flows was a clerical transposition of numbers in the English translation; the Japanese version was correct.
Management Commentary and Risks
Management, represented by Takashi Okubo, Global Head of Investor Relations, clarified the nature of the errors:
- Reason for Correction 1: In Appendix 3 (Reconciliation from Reported to Core/Underlying Core), 4.5 billion yen of financial income/expenses was incorrectly categorized under "Shire acquisition related costs."
- Reason for Correction 2: In the English version of the Statement of Cash Flows, the ending cash balance contained a transposed number error.
- Materiality Assessment: Management does not believe either error or its correction materially impacts the financial statements.
- XBRL Data: No corrections were required for the XBRL data submitted on the same date.
Important Facts for Investors to Verify
- Verify that the corrected "Reconciliation from Reported to Core/Underlying Core" table is being used for analysis, as the original filing contained a misclassification of 4.5 billion yen.
- Confirm the correct ending balance for "Cash and cash equivalents" in the English version of the Statement of Cash Flows, as the original contained a transposition error.
- Note that Reported and Core Operating Income figures remain unchanged by these corrections.